PFAS Exposure Linked to Higher Risk

What did the NIH study find about PFAS and breast cancer?

Researchers measured PFAS in blood collected before diagnosis. Comparing the highest exposure group with the lowest, ER-negative breast cancer rates were 67% higher for PFOA and 93% higher for PFOS. These are relative differences, not percentage-point increases in an individual's probability of cancer. NIH announced the findings on November 5, with the research published in the Journal of Clinical Oncology. [NIH research announcement](https://www.nih.gov/news-events/news-releases/two-forever-chemicals-associated-higher-risk-aggressive-breast-cancer-nih-analysis).

Participants had a sister previously diagnosed with breast cancer, which matters when considering how broadly the findings apply. Measuring exposure before diagnosis strengthens the study's timing, but an observational association cannot exclude other explanations. The results also do not demonstrate that reducing PFAS exposure prevents breast cancer.

What is ER-negative breast cancer, and why does the distinction matter?

Breast cancer includes several diseases with different biological characteristics. Clinicians test tumor tissue for estrogen receptors, progesterone receptors, and HER2 because these results help determine which treatments may work. Hormone therapies interfere with hormone production or signaling; cancers lacking both estrogen and progesterone receptors do not respond to these treatments. [National Cancer Institute hormone therapy guidance](https://www.cancer.gov/types/breast/treatment/hormone-therapy).

ER-negative does not automatically mean triple-negative. Triple-negative breast cancer also lacks progesterone receptors and is HER2-negative. An ER-negative tumor may have other features that create treatment options, so its full biomarker profile matters. This distinction also matters in research: a finding involving one receptor-defined group should not be presented as applying equally to every breast cancer subtype. [National Cancer Institute explanation of triple-negative breast cancer](https://www.cancer.gov/types/breast/breast-cancer-types/triple-negative).

What can people do about possible PFAS exposure?

A practical starting point is an exposure history: drinking-water contamination, relevant workplace contact, and local advice about contaminated food. Depending on the source, exposure reduction may involve appropriate water filtration, an alternative water supply, or following advisories about locally caught fish. Measures should respond to documented conditions rather than assuming every household has the same exposure. ATSDR recommends tailoring these decisions to the person's circumstances. [ATSDR clinical evaluation and management guidance](https://www.atsdr.cdc.gov/pfas/hcp/clinical-overview/clinical-evaluation-management.html).

A PFAS blood test measures selected chemicals in the bloodstream; it does not diagnose breast cancer or establish whether an existing illness was caused by exposure. It also cannot predict or rule out future health problems. Testing may help some people understand exposure, but its benefits and limitations should be discussed before ordering it. A result should not be interpreted as a personalized cancer forecast. [ATSDR guidance on PFAS testing](https://www.atsdr.cdc.gov/pfas/blood-testing/index.html).